Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways.

The extracellular matrix protein tenascin (TN) is expressed with precise temporo-spatial patterns during embryonic and fetal development and is induced in healing wounds, inflammatory lesions and solid tumors. These tissue patterns suggest that TN synthesis may be modulated by soluble factors present in developing tissues or released from injured, inflammatory or neoplastic cells. To characterize the extrinsic control of human TN we examined the effects of several signalling molecules on cultured neural, melanocytic and fibroblastic cells. Results obtained with alpha TN antibodies in enzyme-linked immunosorbent and immunoprecipitation assays indicate that TN expression is tightly regulated in a cell type-specific manner: (1) Primitive neuroectodermal tumor (PNET) cells grown in chemically defined, serum-free media show up to > 100-fold TN induction in response to fibroblast growth factors (aFGF, bFGF, K-FGF) and phorbol ester, independent of changes in cell proliferation or total protein synthesis; no induction is seen in PNET cultures stimulated with serum or other growth and differentiation factors. (2) Normal melanocytes, which require FGF and phorbol ester for survival in vitro, fail to express TN; however, they produce TN following oncogenic transformation. (3) Fibroblasts derived from disparate tissues differ up to 100-fold in basal TN production; for example, fetal lung fibroblasts are TNhigh, but conjunctival fibroblasts derived from the same donors and fetal leptomeningeal cells are TNlow. (4) TNlow fibroblasts treated with interleukin-1, tumor necrosis factor-alpha, and interleukin-4 show up to > 100-fold increased TN secretion and TN incorporation into their extracellular matrix. Transforming growth factor-beta, which acts as an inducer of fibronectin, collagen, and integrin-type matrix receptors, has variable effects on fibroblast TN, ranging from increased deposition in the extracellular matrix of fetal conjunctival fibroblasts to reduced secretion in newborn foreskin fibroblasts. In contrast, FGFs (which are potent fibroblast mitogens), phorbol ester, bone morphogenetic proteins, and several other factors tested produced no discernible effects on fibroblast TN expression. These findings suggest that discrete sets of extrinsic signals modify TN expression in specific cell types, with the effects of a given ligand/receptor system determined by cell type-specific signalling pathways that may be linked to unique cis-regulatory elements of the TN gene. As a result, a limited set of regulatory peptides may produce highly diversified TN distribution patterns in developing and lesional tissues.

[1]  H. Erickson Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. , 1993, Current opinion in cell biology.

[2]  J. Healey,et al.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. , 1993, Cancer research.

[3]  R. Derynck,et al.  Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. , 1993, Science.

[4]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[5]  R. Tucker,et al.  Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. , 1993, Journal of cell science.

[6]  J. Forrester,et al.  Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. , 1992, The Journal of biological chemistry.

[7]  S. Jhanwar,et al.  Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. , 1992, Oncogene.

[8]  M. Herlyn,et al.  Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. , 1992, Oncogene.

[9]  Y. Nishizuka Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.

[10]  V. Lightner,et al.  Expression of human tenascin in synovitis and its regulation by interleukin-1. , 1992, Arthritis and rheumatism.

[11]  S. Hoffman,et al.  Species diversity of neuronectin and cytotactin expression patterns in the vertebrate central nervous system , 1992, Brain Research.

[12]  E. Mackie,et al.  Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. , 1992, The American journal of pathology.

[13]  David J. Anderson,et al.  CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130 , 1992, Cell.

[14]  R. Kolesnick,et al.  Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. , 1992, Science.

[15]  A. Huvos,et al.  Ewing's sarcoma: new approaches to histogenesis and molecular plasticity. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[16]  D. Moscatelli,et al.  The FGF family of growth factors and oncogenes. , 1992, Advances in cancer research.

[17]  R. Halaban,et al.  Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. , 1992, Oncogene.

[18]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[19]  B. Aggarwal,et al.  Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. , 1991, Cancer research.

[20]  M. Sporn,et al.  Cytokines in context , 1991, The Journal of cell biology.

[21]  J. Lanchbury,et al.  Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. , 1991, Journal of immunology.

[22]  S. Gil,et al.  Nerve Growth Factor Mediates Monosialoganglioside‐Induced Release of Fibronectin and J1/Tenascin from C6 Glioma Cells , 1991, Journal of neurochemistry.

[23]  G. Edelman,et al.  Cell adhesion molecules: implications for a molecular histology. , 1991, Annual review of biochemistry.

[24]  R. Ross,et al.  TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. , 1990, Cell.

[25]  G. Edelman,et al.  Identification and characterization of the promoter for the cytotactin gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Thornhill,et al.  IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-gamma. , 1990, Journal of immunology.

[27]  V. Rosen,et al.  Growth factors influencing bone development , 1990, Journal of Cell Science.

[28]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.

[29]  M. Melamed,et al.  Immunohistochemical analysis of human neuronectin expression in normal, reactive, and neoplastic tissues. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  P. Garin‐Chesa,et al.  Cell type-specific control of human neuronectin secretion by polypeptide mediators and phorbol ester. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  L. Greene,et al.  Functional receptors for nerve growth factor on Ewing's sarcoma and Wilm's tumor cells , 1989, Journal of cellular physiology.

[32]  D. Bigner,et al.  Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy , 1989, The Journal of cell biology.

[33]  D. Morton,et al.  IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. , 1989, Journal of immunology.

[34]  T. Triche,et al.  Stimulation of human neuronectin secretion by brain-derived growth factors , 1989, Brain Research.

[35]  P. Ekblom,et al.  Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions [published erratum appears in J Cell Biol 1989 Mar;108(3):following 1175] , 1988, The Journal of cell biology.

[36]  W. Halfter,et al.  Induction of tenascin in healing wounds , 1988, The Journal of cell biology.

[37]  Shigeki,et al.  Tenascin: cDNA cloning and induction by TGF‐beta. , 1988, The EMBO journal.

[38]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.

[39]  M. Melamed,et al.  Definition of an extracellular matrix protein in rostral portions of the human central nervous system , 1988, Brain Research.

[40]  I. Thesleff,et al.  Tenascin is associated with chondrogenic and osteogenic differentiation in vivo and promotes chondrogenesis in vitro , 1987, The Journal of cell biology.

[41]  R. Chiquet‐Ehrismann,et al.  Epithelial-mesenchymal interactions in the developing kidney lead to expression of tenascin in the mesenchyme , 1987, The Journal of cell biology.

[42]  J. Silver,et al.  Differential expression of the human Thy-1 gene in rodent-human somatic cell hybrids [corrected]. , 1987, Journal of immunology.

[43]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[44]  R. Chiquet‐Ehrismann,et al.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis , 1986, Cell.

[45]  G. Edelman,et al.  Altered expression of neuronal cell adhesion molecules induced by nerve injury and repair , 1986, The Journal of cell biology.

[46]  G. Edelman,et al.  Site-restricted expression of cytotactin during development of the chicken embryo , 1986, The Journal of cell biology.

[47]  H. Erickson,et al.  A six-armed oligomer isolated from cell surface fibronectin preparations , 1984, Nature.

[48]  D. Bigner,et al.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. , 1983, Cancer research.

[49]  Ruddle Fh,et al.  Somatic cell genetic analysis of human cell surface antigens. , 1982 .